Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-038758
Filing Date
2025-03-13
Accepted
2025-03-13 16:15:23
Documents
88
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K elvn-20241231.htm   iXBRL 10-K 3489726
2 EX-10.16 elvn-ex10_16.htm EX-10.16 53762
3 EX-19.1 elvn-ex19_1.htm EX-19.1 135448
4 EX-21.1 elvn-ex21_1.htm EX-21.1 5195
5 EX-23.1 elvn-ex23_1.htm EX-23.1 3077
6 EX-31.1 elvn-ex31_1.htm EX-31.1 15846
7 EX-31.2 elvn-ex31_2.htm EX-31.2 15831
8 EX-32.1 elvn-ex32_1.htm EX-32.1 9822
9 EX-32.2 elvn-ex32_2.htm EX-32.2 9812
10 GRAPHIC img252695981_0.jpg GRAPHIC 695121
11 GRAPHIC img252695981_1.jpg GRAPHIC 695121
12 GRAPHIC img252695981_2.jpg GRAPHIC 695121
  Complete submission text file 0000950170-25-038758.txt   17036413

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT elvn-20241231.xsd EX-101.SCH 1489317
91 EXTRACTED XBRL INSTANCE DOCUMENT elvn-20241231_htm.xml XML 1908627
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Filer) CIK: 0001672619 (see all company filings)

EIN.: 811523849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39247 | Film No.: 25735955
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)